" class="no-js "lang="en-US"> Mirela Delibegovic - Medtech Alert
Monday, August 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mirela Delibegovic

Mirela Delibegovic

About Mirela Delibegovic

A successful collaborative researcher with innovative ideas and diverse income streams. Known for strategic inclusive leadership style, dedicated to developing staff and creating strategies for sustainable growth and income. Recognised for creating constructive outcomes for conflict situations and balancing listening skills and making difficult decisions. Managing commercial projects in drug discovery, industrial and discovery science projects.

Related Story

Diseases

 Researchers Investigate New Treatment for Diabetes to Combat Sight Loss | Pharmtech Focus

Researchers Investigate New Treatment for Diabetes to Combat Sight Loss

September 22 2021

Researchers at the University of Aberdeen are investigating a new treatment for diabetes which they […]